Abstract: The disclosure provides an article comprising a substrate having a surface including (i) a matrix of an optically transparent polymeric material having a first surface functionality, and (ii) at least one plasma-treated surface region comprising a portion of the surface, wherein each surface region comprises a second surface functionality, and wherein the first surface functionality and the second surface functionality are different The disclosure also provides a method for forming an article, the method comprising: (a) providing a substrate having a surface including an optically transparent polymeric material, (b) contacting the surface with a first plasma to create at least one plasma-treated surface region comprising a portion of the surface, each plasma-treated surface region having a first surface functionality, and (c) contacting each plasma-treated surface region with a second plasma to create a second surface functionality.

Abstract: Compositions of hyaluronic acid (HA) conjugated with antibiotics are disclosed for a rapid release antibiotic delivery system into a closed space to achieve rapid therapeutic range within 24 hours and effective elimination of the antibiotic within 80-120 hours. In particular, this invention is directed to compositions, method of preparation, and method of treatment to prevent invention using porous and non-porous embodiments of hyaluronic acid polymer conjugated with antibiotics or other therapeutic agents for rapid therapeutic delivery and controlled reduction of therapeutic dosages of antibiotics to prevent invention and reduce antibiotic resistance. Low concentration of crosslinkers conjugated with HA as well as using porogens and functional group modifiers allow other therapeutic to be conjugated to HA such as sugars and steroids. Suspension of HA conjugates in chitosan enable additional treatment means. Anti-cancer therapeutic agents may also be conjugated for controlled release using this system.

Abstract: An ophthalmological device comprises an implant member carrying an antifibrotic agent that is released slowly over a prolonged period when inserted into a wound in an eye produced by surgery. The member is placed in the vicinity of a wound created during the surgery to inhibit inflammatory cell proliferation, thereby preventing the growth of fibrous tissue after the eye surgery.

Abstract: An ophthalmological device comprises an implant member carrying an antifibrotic agent that is released slowly over a prolonged period when inserted into a wound in an eye produced by surgery. The member is placed in the vicinity of a wound created during the surgery to inhibit inflammatory cell proliferation, thereby preventing the growth of fibrous tissue after the eye surgery.